Which ICD‑10‑CM code should I use for a fecal occult blood test (FOBT) performed as colorectal cancer screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD-10-CM Coding for FOBT Screening

For fecal occult blood test (FOBT) performed as colorectal cancer screening in average-risk, asymptomatic adults, use ICD-10-CM code Z12.11 (Encounter for screening for malignant neoplasm of colon).

Coding Rationale

  • Z12.11 is the appropriate screening code when FOBT is performed for colorectal cancer screening in asymptomatic patients without signs, symptoms, or personal history of colorectal disease 1.

  • This code applies to all stool-based screening tests including high-sensitivity guaiac FOBT (gFOBT), fecal immunochemical test (FIT), and multitarget stool DNA tests when used for screening purposes 1.

When to Use This Code

  • Patient must be asymptomatic with no gastrointestinal symptoms, no prior colorectal cancer, no adenomatous polyps, and no inflammatory bowel disease 1.

  • Screening age range: Adults aged 45-75 years for routine screening, with individualized decisions for ages 76-85 years 1.

  • Annual screening intervals are recommended for both high-sensitivity gFOBT and FIT 1.

Critical Coding Pitfalls to Avoid

  • Do NOT use Z12.11 if the patient has symptoms (such as rectal bleeding, abdominal pain, change in bowel habits, or anemia). In symptomatic patients, code the presenting symptom instead (e.g., R19.5 for abnormal fecal contents, K62.5 for gastrointestinal hemorrhage) 1.

  • Do NOT use Z12.11 for surveillance testing in patients with prior polyps or colorectal cancer history. These patients require different codes based on their specific history 1.

  • Do NOT use Z12.11 for diagnostic FOBT ordered to evaluate an abnormal finding or follow up a positive screening test. The diagnostic indication should be coded instead 1.

Additional Coding Considerations

  • For high-risk patients (family history of colorectal cancer, Lynch syndrome, familial adenomatous polyposis), Z12.11 may still be appropriate for the screening encounter, but consider adding secondary codes for family history (Z80.0) or genetic susceptibility (Z15.09) to document increased risk 1.

  • Insurance coverage typically requires Z12.11 for preventive screening benefits to apply, as this designates the service as screening rather than diagnostic 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‑10‑CM) code for a bilateral adductor (groin) strain?
Do the ICD-10 codes listed cover all the labs ordered for insurance coverage?
What are the risk factors for colon (colorectal) cancer?
What is the recommended screening schedule for an adult of average risk for colorectal cancer using the Fecal Immunochemical Test (FIT)?
When should a 45-year-old average-risk woman begin colorectal cancer screening and how often?
What is the normal fasting insulin range in adults and how should elevated fasting insulin be evaluated and managed?
In an elderly patient on warfarin who had a ground‑level fall with no loss of consciousness, normal Glasgow Coma Scale, and no obvious head injury, should an emergent non‑contrast head CT be performed?
What is the recommended weight loss goal and management strategy (diet, exercise, behavioral support, and pharmacotherapy) for a reproductive‑age woman with polycystic ovary syndrome?
In a 71-year-old woman with urgency-type overactive bladder who is taking warfarin, atorvastatin, losartan, and trazodone, what is an appropriate first-line pharmacologic agent that will not interact with her current medications?
What is the appropriate initial management of flash pulmonary edema?
Given a reticulocyte percentage of 1.56%, absolute reticulocyte count of 0.074 ×10⁹/L, hemoglobin‑reticulocyte quotient of 28.8, and immature reticulocyte fraction of 20.2%, what is the most likely interpretation and what diagnostic steps should be taken next?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.